Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 2Thrombocytosis 1Thrombocytopenia 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Follicular 1Kidney Neoplasms 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Anemia 1

Interventions

Peripheral Blood Stem Cell Transplantation 2siltuximab 1fludarabine phosphate 1ferric gluconate 1Transplantation 1Tacrolimus 1Pluvicto 1Methotrexate 1Iron-Dextran Complex 1Iron 1Holistic Health 1Filgrastim 1Erythrocyte Transfusion 1Epoetin Alfa 1Busulfan 1Blood Transfusion 1Blood Component Transfusion 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Anemia × siltuximab × Clear all
NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase EARLY_PHASE1 Withdrawn
Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡